This book will provide an overview of the chemistry of nanocarrier design and the considerations that need to be made when developing a nanomedicine.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Design Considerations for Properties of Nanocarriers on the Disposition and Efficiency of Drug and Gene Delivery; Targeting Cyclins and Cyclin-Dependent Kinases Involved in Cell Cycle Regulation by RNAi as a Potential Cancer Therapy; Nanoparticle carriers to overcome biological barriers to siRNA delivery; Magnetic targeting as a vehicle for delivery of nanomedicines; Development of Theranostics - Imaging Considerations and Targeted Drug Delivery; The Role of Imaging in Nanomedicine Development and Clinical Translation; Anticancer agent-incorporating polymeric micelles: from bench to bedside; Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101; Nanodelivery Strategies in Breast Cancer Chemotherapy; Developing a Predictable Regulatory Path for Nanomedicines by Accurate and Objective Particle Measurement; Nanomedicine: Promises and Challenges; The Challenge of Regulating Nanomedicine: Key Issues; Doxil® - The First FDA-Approved Nano-Drug: From Basics via CMC, Cell Culture and Animal Studies to Clinical Use
Design Considerations for Properties of Nanocarriers on the Disposition and Efficiency of Drug and Gene Delivery; Targeting Cyclins and Cyclin-Dependent Kinases Involved in Cell Cycle Regulation by RNAi as a Potential Cancer Therapy; Nanoparticle carriers to overcome biological barriers to siRNA delivery; Magnetic targeting as a vehicle for delivery of nanomedicines; Development of Theranostics - Imaging Considerations and Targeted Drug Delivery; The Role of Imaging in Nanomedicine Development and Clinical Translation; Anticancer agent-incorporating polymeric micelles: from bench to bedside; Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101; Nanodelivery Strategies in Breast Cancer Chemotherapy; Developing a Predictable Regulatory Path for Nanomedicines by Accurate and Objective Particle Measurement; Nanomedicine: Promises and Challenges; The Challenge of Regulating Nanomedicine: Key Issues; Doxil® - The First FDA-Approved Nano-Drug: From Basics via CMC, Cell Culture and Animal Studies to Clinical Use
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826